(Q51496275)

English

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

scientific article published in May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Paulos Berhanu

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Mark S Kipnes

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Mehmood A Khan

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Alfonso T Perez

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Stuart F Kupfer

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Robert C Spanheimer

6

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Seleshi Demissie

7

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Penny R Fleck

8

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

language of work or name

0 references

publication date

1 May 2006

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Diabetes and Vascular Disease Research

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

39-44

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Lipids and lipoproteins in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Tr

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.005

21 January 2018

Identifiers

10.3132/DVDR.2006.005

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/16784180

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51496275&oldid=1512252730"